Bayer AG (XSWX:BAYN) Marketable Securities: CHF848 Mil (As of Mar. 2026)


XSWX:BAYN Bayer AG XSWX:BAYN
54 GF Score
Price CHF43.29
GF Value CHF24.61
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bayer AG Marketable Securities?

Bayer AG XSWX:BAYN 54 Marketable Securities is CHF848 Mil as of Mar. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 54/100 and a GF Value™ of CHF24.61 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Bayer AG's Marketable Securities for the quarter that ended in Mar. 2026 was CHF848 Mil.

Bayer AG's annual Marketable Securities declined from Dec. 2023 (CHF4,414 Mil) to Dec. 2024 (CHF1,770 Mil) and declined from Dec. 2024 (CHF1,770 Mil) to Dec. 2025 (CHF1,106 Mil).

Bayer AG  (XSWX:BAYN) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Bayer AG Marketable Securities Related Terms

Bayer AG Marketable Securities Historical Data

* Premium members only.

The historical data trend for Bayer AG's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Marketable Securities Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,304.15 4,916.56 4,413.59 1,770.13 1,105.77

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,307.73 879.79 1,256.75 1,105.77 848.28
XSWX:BAYN
54GF Score
Bayer AG XSWX:BAYN
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of CHF848 Mil mean?
Bayer AG (XSWX:BAYN) has a Marketable Securities of CHF848 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Bayer AG and its competitors.
Is Bayer AG's Marketable Securities too high?
Bayer AG's current Marketable Securities is CHF848 Mil. Overall, Bayer AG has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Marketable Securities compare to LLY and JNJ?
Bayer AG's Marketable Securities of CHF848 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Bayer AG and its competitors. Bayer AG's current Marketable Securities is CHF848 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.61, compared to a current price of CHF43.29 — trading 75.9% above its estimated fair value. The current Marketable Securities is CHF848 Mil. Bayer AG's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Marketable Securities is CHF848 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XSWX:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of CHF43.29 is trading 75.9% above its estimated GF Value™ of CHF24.61. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XSWX:BAYN:

  • Marketable Securities: CHF848 Mil
  • GF Value™: CHF24.61 vs. price of CHF43.29 (75.9% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
54GF Score

Get the complete analysis for XSWX:BAYN

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF43.29
Price
CHF24.61
GF Value